ArticleDrug delivery and translational research2025

Combination therapy using Cel-CSO/Taxol NPs for reversing drug resistance in breast cancer through inhibiting PI3K/AKT/NF-κB/HIF-1α pathway.

Huahui Zeng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.